• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

    5/15/25 4:35:08 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORIC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Oric Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    68622P109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,572,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,572,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,572,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,572,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,572,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,572,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,312,800.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,312,800.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,312,800.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,312,800.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,312,800.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,312,800.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,312,800.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,312,800.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,312,800.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,259,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,259,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,259,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,259,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,259,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,259,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown (Aggregator) LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,259,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,259,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,259,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,572,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,572,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,572,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Ott David C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,572,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,572,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,572,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,572,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,572,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,572,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Oric Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    240 E. Grand Ave, 2nd Floor, South San Francisco, California, 94080
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOD GP and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    68622P109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    VGI: 6,572,700 VGI provides managerial services to VGOP and VGOD. VGI has the authority to dispose of and vote the shares of Common Stock that VGOP and VGOD directly own. VGI does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, VGI may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own. VGI beneficially owns 6,572,700 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP and 2,259,900 shares of Common Stock directly owned by VGOD. Opportunities Parent: 6,572,700 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP (which consists of the shares of Common Stock that VGOP directly owns), and is the sole member of VGOD GP, which has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP (which consists of the shares of Common Stock that VGOD directly owns). Opportunities Parent does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own. Opportunities Parent beneficially owns 6,572,700 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP and 2,259,900 shares of Common Stock directly owned by VGOD. Opportunities GP: 4,312,800 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. Opportunities GP does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns. Opportunities GP beneficially owns 4,312,800 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP. Opportunities Portfolio GP: 4,312,800 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns. Opportunities Portfolio GP does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns. Opportunities Portfolio GP beneficially owns 4,312,800 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP. VGOP: 4,312,800 VGOP has the authority to dispose of and vote the 4,312,800 shares of Common Stock that it directly owns, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. VGOD GP: 2,259,900 VGOD GP serves as the sole member of VGOD Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP, which consists of the shares of Common Stock that VGOD directly owns. In addition, VGOD GP is the general partner of each of Viking Global Opportunities Drawdown (Internal) LP, Viking Global Opportunities Drawdown (Onshore) LP, and Viking Global Opportunities Drawdown (Offshore) LP. VGOD GP does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, VGOD GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns. VGOD GP beneficially owns 2,259,900 shares of Common Stock consisting of 2,259,900 shares of Common Stock directly owned by VGOD. VGOD Portfolio GP: 2,259,900 VGOD Portfolio GP serves as the general partner of VGOD and has the authority to dispose of and vote the shares of Common Stock that VGOD directly owns. VGOD Portfolio GP does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, VGOD Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns. VGOD Portfolio GP beneficially owns 2,259,900 shares of Common Stock consisting of 2,259,900 shares of Common Stock directly owned by VGOD. VGOD: 2,259,900 VGOD has the authority to dispose of and vote the 2,259,900 shares of Common Stock that it directly owns, which power may be exercised by its general partner, VGOD Portfolio GP, and by VGI, an affiliate of VGOD Portfolio GP, which provides managerial services to VGOD. Viking Global Opportunities Drawdown (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Drawdown (Internal) LP (a Delaware limited partnership), through its investment in Viking Global Opportunities Drawdown (Onshore) LP (a Delaware limited partnership), invest substantially all of their assets in VGOD. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6,572,700 Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock. Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own. Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 6,572,700 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP and 2,259,900 shares of Common Stock directly owned by VGOD.
    (b)Percent of class:

    The percentages set forth herein are based on 71,078,511 shares of Common Stock outstanding as of March 31, 2025, as reported in the Issuer's proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the "Commission") on April 23, 2025. VGI: 9.2% Opportunities Parent: 9.2% Opportunities GP: 6.1% Opportunities Portfolio GP: 6.1% VGOP: 6.1% VGOD GP: 3.2% VGOD Portfolio GP: 3.2% VGOD: 3.2% O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 9.2%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 6,572,700 Opportunities Parent: 6,572,700 Opportunities GP: 4,312,800 Opportunities Portfolio GP: 4,312,800 VGOP: 4,312,800 VGOD GP: 2,259,900 VGOD Portfolio GP: 2,259,900 VGOD: 2,259,900 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6,572,700

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 6,572,700 Opportunities Parent: 6,572,700 Opportunities GP: 4,312,800 Opportunities Portfolio GP: 4,312,800 VGOP: 4,312,800 VGOD GP: 2,259,900 VGOD Portfolio GP: 2,259,900 VGOD: 2,259,900 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 6,572,700

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities Drawdown GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities Drawdown Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
    Date:05/15/2025
     
    Viking Global Opportunities Drawdown (Aggregator) LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
    Date:05/15/2025
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:05/15/2025
     
    Ott David C.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
    Date:05/15/2025
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
    Date:05/15/2025

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $ORIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORIC

    DatePrice TargetRatingAnalyst
    10/31/2024$20.00Overweight
    Wells Fargo
    9/6/2024$20.00Buy
    Stifel
    2/23/2024Overweight
    Cantor Fitzgerald
    9/22/2023$8.00Outperform
    Wedbush
    3/23/2023$16.00Neutral → Buy
    H.C. Wainwright
    3/21/2023$15.00Neutral → Buy
    Guggenheim
    3/16/2023$14.00Perform → Outperform
    Oppenheimer
    7/18/2022Perform
    Oppenheimer
    More analyst ratings

    $ORIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

      Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of regi

      5/5/25 4:05:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2025 (the "Grant Date"), ORIC granted a total of 32,400 non-qualified stock options and 5,200 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock opti

      5/2/25 4:30:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of a poster at the 2025 American Association for Cancer Research (AACR) Annual Meeting, highlighting preclinical data on ORIC-944, a potent, highly selective, orally bioavailable allosteric inhibitor of PRC2, which demonstrated synergistic activity and improved progression-free survival (PFS) when combined with androgen receptor pathway inhibitors (ARPIs) in models of prostate cancer. "We are excited by the potential of

      4/28/25 4:30:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kunkel Lori Anne exercised 48,166 shares at a strike of $4.85, increasing direct ownership by 235% to 68,666 units (SEC Form 4)

      4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

      3/4/25 5:27:04 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director You Angie

      4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

      1/6/25 4:47:57 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kunkel Lori Anne

      4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

      1/6/25 4:46:39 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on ORIC Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      10/31/24 6:33:23 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on ORIC Pharmaceuticals with a new price target

      Stifel initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $20.00

      9/6/24 7:48:52 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals

      Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals with a rating of Overweight

      2/23/24 7:13:54 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

      SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      11/14/24 5:54:12 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

      SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      11/14/24 5:47:31 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

      SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      11/14/24 5:14:58 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Leadership Updates

    Live Leadership Updates

    See more
    • ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

      Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected

      2/18/25 4:05:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

      Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO and SAN DIEGO, J

      1/13/25 8:05:00 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

      Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resis

      11/12/24 4:05:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

      SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      5/15/25 5:47:21 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

      SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      5/15/25 4:35:08 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Oric Pharmaceuticals Inc.

      10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

      5/5/25 4:20:18 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Financials

    Live finance-specific insights

    See more
    • Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

      Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11

      12/11/23 12:00:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

      CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion

      10/21/23 7:30:00 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. In conjunction with the ESMO presentations, OR

      10/17/23 4:30:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care